Earnings Call Summary | Oncolytics Biotech(ONCY.US) Q1 2024 Earnings Conference
Earnings Call Summary | Oncolytics Biotech(ONCY.US) Q1 2024 Earnings Conference
The following is a summary of the Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript:
以下是Oncolytics Biotech, Inc.（ONCY）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Oncolytics Biotech reported a cash position of $29.6 million at the end of Q1 2024, down from $34.9 million at the end of 2023.
The company reported a net loss of $6.9 million for the first quarter of 2024, a slight increase from a net loss of $6.4 million in the first quarter of 2023.
Research and development expenses for Q1 2024 amounted to $5.7 million, primarily because of increased manufacturing expenses and preparations for upcoming product fills.
Oncolytics Biotech報告稱，截至2024年第一季度末，現金狀況爲2960萬美元，低於2023年底的3,490萬美元。
該公司報告稱，2024年第一季度淨虧損690萬美元，較2023年第一季度的淨虧損640萬美元略有增加。
2024年第一季度的研發費用爲570萬美元，這主要是由於製造費用增加以及爲即將到來的產品灌裝做準備。
Business Progress:
業務進展：
Oncolytics focused on advancing its proprietary immunotherapeutic product candidate, pelareorep.
Enrollment in the anal cancer cohort of the GOBLET study has been extended, potentially leading to a new registrational indication.
The company received regulatory approval to move forward with the pela and modified FOLFIRINOX combination study.
Overall survival data from the BRACELET-1 breast cancer study is expected in H2 2024.
Oncolytics plans to initiate registration-enabling studies in breast and pancreatic cancer.
Oncolytics專注於推進其專有的免疫療法候選產品pelareorep。
GOBLET研究的****癌隊列的註冊人數已延長，這可能會導致新的註冊適應症。
該公司獲得了監管部門的批准，可以推進Pela和改良的FOLFIRINOX聯合研究。
BRACELET-1 乳腺癌研究的總體存活數據預計將在2024年下半年公佈。
Oncolytics計劃啓動乳腺癌和胰腺癌的註冊研究。
More details: Oncolytics Biotech IR
更多詳情： 腫瘤生物技術 IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。